Home > News > Venture firms still don't see the nanotech in biosciences
October 1st, 2003
Venture firms still don't see the nanotech in biosciences
Timing is everything, say Oregon's venture fund managers. The state of nanotechnology in the biosciences is too early for venture capital investing, believes Gerry Langeler, of Seattle-based OVP Venture Partners, the oldest venture firm in the Pacific Northwest, currently with $195 million to invest.
Harris & Harris Group Portfolio Company, AgBiome, Announces Partnership to Accelerate the Discovery of Next Generation Insect-Resistant Crops July 1st, 2015
Nanometrics to Participate in 7th Annual CEO Investor Summit 2015: Investor Event Held Concurrently With SEMICON West in San Francisco June 25th, 2015
Harris & Harris Group Portfolio Company D-Wave Systems Announces 1,000 Qubit Processor and is Discussed in the Economist June 23rd, 2015
Nanowire LED Innovator Aledia Completes $31 Million Series B Financing June 18th, 2015